Immunohistochemical detection of p140(trkA) and p75(LNGFR) neurotrophin receptors in neuroblastoma

In neuroblastoma, high levels of mRNA for p140(trkA) and p75(LNGFR) neurotrophin receptors are predictive of favorable outcome. Their evaluation by Northern blot, however, requires substantial amounts of tissue and this prevents their routine evaluation as well as the possibility for multicenter studies to be easily carried out. In an attempt to overcome these limitations, the feasibility and reliability of determining both neurotrophin receptors on cryostat sections by immunohistochemistry were assessed, and these findings were compared to those obtained from Northern blot analysis. Primary tumor samples from 28 untreated patients at all stages were evaluated by using H10 anti-p140(trkA) and ME20.4 anti-p75(LNGFR) mAbs. Although weak, positive immunostaining was found in 9 of 28 tumors for p140(trkA) and in 5 of 28 tumors for p75(LNGFR). AS compared to Northern blot, the concordance rate was 79% (22 of 28 cases) for p140(trkA) (p < 0.05) and 71% (20 of 23 cases) for p75(LNGFR) (p < 0.05). No case negative for Northern blot was found to be positive with immunohistochemistry. Since only high mRNA levels for both receptors have been shown to be clinically relevant: their immunohistochemical detection, although less sensitive than Northern blot, can be just as sufficient and reliable as a prognostic tool, and possibly with a better cost-benefit ratio.